2021 Institutional Presentation

Institutional Presentation

November, 2021

Disclaimer

This presentation contains forward-looking statements that are exclusively related to the prospects of the business, its operating and financial results, and prospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business and its continued access to capital to fund its business plan. Forward-looking statements substantially depend on the market conditions, government regulations, competitive pressures, the performance of the Brazilian economy and the industry, among other factors, as well as the risks shown in our filed disclosure documents, and are therefore subject to change without prior notice.

In addition, unaudited information herein reflects management's interpretation of information taken from its financial statements and their respective adjustments, which were prepared in accordance with market practices and for the sole purpose of a more detailed and specific analysis of our results. Therefore, these additional considerations and data must also be analyzed and interpreted independently by shareholders and market agents, who should carry out their own analysis and draw their own conclusions from the information reported herein. No data or interpretative analysis provided

by our management should be treated as a guarantee of future performance or results and are merely illustrative of our directors' vision of our results.

The management is not responsible for compliance or accuracy of the data from this report, which must be considered as for informational purposes only, and should not override the analysis of our audited consolidated financial statements for purposes of a decision to invest in our stock or for any other purpose.

2

Hypera Pharma: One of the biggest pharma companies in Brazil1

Fast-growing	Unique	Innovation	Large scale	Capital
and resilient	branded	supported a	integrated	allocation
pharma	portfolio	robust R&D	business	focused on
market		center,	platform	sustainable
		collaborations		growth and
		and		cash return
		partnerships

3 Note: ¹in sell-out PPP 2020, according to IQVIA

Fast-growing and resilient pharma market

4

Brazil is the largest pharma market in Latin America and should grow ahead of the Emerging Markets average until 2024

Latin American Market¹

(USD)

	Other
27.0 bi	31.3 bi
(46%)	(54%)

Forecasted 2020-24 CAGR¹

	(USD)
Russia
13%
	10%
India	8%
EM	7%
China	4%
Global	4%
UK	4%
USA	3%
Others	5%

5 Note: ¹in sell-out PPP, according to IQVIA